Myelodysplastic Syndromes: Overview, Diagnosis, Therapy, and More

A roundtable discussion, moderated by Hana Safah, MD, of the Tulane University School of Medicine, focused on the latest data in myelodysplastic syndromes presented at the 65th ASH Annual Meeting & Exposition. Dr. Safah was joined by Jamile Shammo, MD; Andrew Brunner, MD; and Tiffany Tanaka, MD.
In the first segment of the roundtable series, Dr. Safah gave an overview of myelodysplastic syndromes and addressed the current state of patient treatment and care.

[@Ourania.b]

If you had an AML patient with mutations IDH2, SF3B1, ASXL1, NPM1 and a history of heart disease would you choose low intensity chemo with a menin inhibitor or high intensity chemo with a menin inhibitor?